Nuo Therapeutics, Revenue Growth Rates (CMXI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nuo Therapeutics, Inc.  (CMXI)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

CMXI's Revenue Growth by Quarter and Year

Nuo Therapeutics,'s Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CMXI Revenue (in millions $) FY 2014 FY 2013 FY 2012 FY 2011
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1.77
1st Quarter March 0.00
FY 1.77





CMXI Revenue second quarter 2014 Y/Y Growth Comment
Nuo Therapeutics, Inc. in the second quarter 2014 achieved Revenue of $ 1.77 millions compare to recorded in same quarter a year ago.

Looking into second quarter 2014 results within Medical Laboratories industry 3 other companies have achieved higher Revenue growth. While Nuo Therapeutics, Inc.' s Revenue no change of 0% ranks overall at the positon no. 842 in the second quarter 2014.


CMXI Revenue ( Y/Y Growth %) 2014
 2013 2012 2011
4th Quarter December - - - -20.26 %
3rd Quarter September - - - 64.76 %
2nd Quarter June - - -49.85 % 91.48 %
1st Quarter March - - -3.72 % -34.42 %
FY   - - -63.78 % -

Financial Statements
Nuo Therapeutics,'s second quarter 2014 Revenue $ 1.77 millions CMXI's Income Statement
Nuo Therapeutics,'s second quarter 2013 Revenue $ 0.00 millions Quarterly CMXI's Income Statement


CMXI Revenue (Quarter on Quarter Growth %)

 2014
 2013 2012 2011
4th Quarter December - - - -46.53 %
3rd Quarter September - - - 2.67 %
2nd Quarter June - - -27.47 % 39.26 %
1st Quarter March - - 25.95 % 4.31 %
FY (Year on Year)   - - -63.78 % -


Back to CMXI Growth rate Comparisons >> Back to CMXI Growth rate Comparisons >>


Revenue second quarter 2014 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #108
Overall #842

Revenue Y/Y Growth Statistics
High Average Low
27.88 % 7.59 % -8.64 %
  (Sep 30 2014)
Revenue second quarter 2014 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #108
Overall #842
Revenue Y/Y Growth Statistics
High Average Low
27.88 % 7.59 % -8.64 %
  (Sep 30 2014)

Revenue by Quarter for the Fiscal Years 2011, 2012, 2013, 2014

Nuo Therapeutics,'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CMXI's II. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CMXI's II. Quarter Q/Q Revenue Comment


Nuo Therapeutics,'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2014)		 12 Months Ending
(Jun 30 2014)		 12 Months Ending
(Mar 31 2014)		 12 Months Ending
(Dec 31 2013)		 12 Months Ending
(Sep 30 2013)
Cumulative Revenue 12 Months Ending $ 9.33 $ 11.00 $ 11.10 $ 11.57 $ 10.21
Y / Y Revenue Growth (TTM) -8.64 % 27.88 % 12.52 % 9.53 % -10.57 %
Year on Year Revenue Growth Overall Ranking # 2318 # 2300 # 517 # 529 # 0
Seqeuential Revenue Change (TTM) -15.22 % -0.88 % -4.07 % 13.33 % 18.68 %
Seq. Revenue Growth (TTM) Overall Ranking # 842 # 842 # 3421 # 3426 # 0


Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2014 Nuo Therapeutics, reported a decrease in Revenue by -8.64% year on year, to $9 millions, compare to the 27.88% growth at Jun 30 2014.

In the Healthcare sector 234 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2300 to 2318.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 4
Healthcare Sector # 235
Overall # 2318

Revenue TTM Y/Y Growth Statistics
High Average Low
27.88 %
 7.59 %
-8.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 108
S&P 500 # 842
Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2014 Nuo Therapeutics, reported a decrease in Revenue by -8.64% year on year, to $9 millions, compare to the 27.88% growth at Jun 30 2014.

In the Healthcare sector 234 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2300 to 2318.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 4
Healthcare Sector # 235
Overall # 2318

Revenue TTM Y/Y Growth Statistics
High Average Low
27.88 %
7.59 %
-8.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 108
S&P 500 # 842




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CMXI's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Nuo Therapeutics, Revenue Growth Rates (CMXI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.